Sucrose octasulfate
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Sucrose octasulfate
Description:
Sucrose octasulfate, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate can be used in the study of chronic wound healing[1][2][3].UNSPSC:
12352005Target:
MMP; Somatostatin ReceptorRelated Pathways:
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal SignalingApplications:
COVID-19-immunoregulationField of Research:
Inflammation/ImmunologySmiles:
O=S(OC[C@@]1([C@H]([C@@H]([C@H](O1)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)(O)=OMolecular Formula:
C12H22O35S8Molecular Weight:
982.80References & Citations:
[1]Edmonds M, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer) : an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6 (3) :186-196.|[2]Dissemond J, et al. Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden [Sucrose octasulfate-evidence in the treatment of chronic wounds]. Hautarzt. 2020 Oct;71 (10) :791-801. German. |[3]Lucey MR, et al. Sucrose octasulfate stimulates gastric somatostatin release. Am J Med. 1991 Aug 8;91 (2A) :52S-57S.Shipping Conditions:
Room temperatureScientific Category:
Reference compound1Clinical Information:
No Development ReportedCAS Number:
[57680-56-5]
